Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Harold Bernstein Sells 16,141 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,141 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.93, for a total value of $434,677.13. Following the transaction, the chief marketing officer directly owned 16,141 shares of the company’s stock, valued at approximately $434,677.13. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Friday, September 4th, Harold Bernstein sold 9,705 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total transaction of $254,465.10.
• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $134,965.89.
• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total value of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total value of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total value of $445,680.62.

Maze Therapeutics Trading Down 0.8%

NASDAQ MAZE traded down $0.22 during trading hours on Friday, reaching $26.43. The company’s stock had a trading volume of 633,043 shares, compared to its average volume of 665,641. The firm has a fifty day simple moving average of $27.00 and a 200-day simple moving average of $28.23. The stock has a market cap of $1.47 billion, a P/E ratio of -10.49 and a beta of 2.16. Maze Therapeutics, Inc. has a 52 week low of $21.95 and a 52 week high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76). Equities analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of MAZE. Squarepoint Ops LLC boosted its stake in Maze Therapeutics by 42.8% during the second quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock worth $580,000 after acquiring an additional 5,822 shares in the last quarter. Frazier Life Sciences Management L.P. raised its holdings in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the period. AXQ Capital LP boosted its position in shares of Maze Therapeutics by 114.1% during the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock worth $453,000 after purchasing an additional 8,098 shares in the last quarter. Braidwell LP acquired a new stake in shares of Maze Therapeutics in the 2nd quarter valued at about $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Maze Therapeutics by 4,054.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock valued at $529,000 after buying an additional 17,312 shares in the last quarter.

Wall Street Analysts Forecast Growth

MAZE has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Maze Therapeutics in a report on Thursday, September 24th. Citigroup began coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, BTIG Research reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $63.40.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.